HCPCS Level II code Q4114 designates a 1 cc vial of Integra flowable wound matrix, an injectable biologic used to support wound healing and tissue regeneration. The code is used to bill for the product rather than a procedure and is relevant across outpatient wound care settings, ambulatory surgical centers, and hospital outpatient departments. Nationally, accurate coding for injectable wound matrices affects product tracking, coverage decisions, and payment consistency for advanced wound care therapies.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical role of the product, typical sites of service, and which payers are commonly involved in coverage determinations. The publication summarizes benchmarking and utilization context where available, highlights common billing modifiers used with injectable biologics, and outlines policy and coverage considerations that influence reimbursement and prior authorization practices. It also provides clinical context for when a flowable wound matrix may be used and notes where input data was not provided.

This summary is intended for national audiences including clinicians, billing professionals, and policy analysts seeking a clear, policy-focused briefing on HCPCS Level II code Q4114 and its role in advanced wound care billing and coverage.